Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R.
Vithayathil M, et al. Among authors: sharma r.
Hepatol Int. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1.
Hepatol Int. 2023.
PMID: 37005953
Free PMC article.